Cagrilintide: Side Effects & Safety
Part of the Cagrilintide Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
Overall Safety Profile
Cagrilintide's safety profile in clinical trials is similar to other incretin-based therapies, with gastrointestinal effects being most common. Safety data is still accumulating as Phase 3 trials are ongoing.
Reported Side Effects
- Nausea: Most common, generally mild to moderate, decreasing over time
- Vomiting and diarrhea: Common GI effects
- Injection site reactions: Mild and transient
- Decreased appetite: Therapeutic effect but can be excessive
Important Limitations
Cagrilintide is still in Phase 3 clinical trials. Long-term safety data (>1 year) is limited. The effects of chronic amylin receptor activation on bone density, pancreatic function, and other organ systems require further characterization.
Potential Contraindications
- Known hypersensitivity to amylin analogs
- Gastroparesis or severe GI motility disorders
- Pregnancy and breastfeeding (no safety data)